TP-0903 is active in models of drug-resistant acute myeloid leukemia

Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that TP-0903 has potent activity against protein kinases related to STAT, AKT, and ERK signaling, as well as cell cycle regulators in biochemical an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Jae Yoon, Buelow, Daelynn R., Garrison, Dominique A., Niu, Mingshan, Eisenmann, Eric D., Huang, Kevin M., Zavorka Thomas, Megan E., Weber, Robert H., Whatcott, Clifford J., Warner, Steve L., Orwick, Shelley J., Carmichael, Bridget, Stahl, Emily, Brinton, Lindsey T., Lapalombella, Rosa, Blachly, James S., Hertlein, Erin, Byrd, John C., Bhatnagar, Bhavana, Baker, Sharyn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714403/
https://www.ncbi.nlm.nih.gov/pubmed/33268594
http://dx.doi.org/10.1172/jci.insight.140169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714403/
https://www.ncbi.nlm.nih.gov/pubmed/33268594
http://dx.doi.org/10.1172/jci.insight.140169

Ejemplares similares